Regulatory Forbearance and the Price of Vaccine Trust: Why Settlement Without Sanction Threatens Public Health

When the European Commission accepted Sanofi’s behavioral commitments to end its antitrust investigation into vaccine disparagement without imposing financial penalties, regulators may have inadvertently signaled that misleading pharmaceutical marketing—even in the vaccine sector—carries manageable reputational costs rather than genuine economic consequences. This choice warrants serious scrutiny from those of us committed to preserving public confidence in immunization-programs/" class="gmj-dict-autolink" title="Dictionary: Immunization Programs">immunization programs.

The distinction between settlement and sanction is not merely procedural. It is philosophical. A fine communicates categorical disapproval and economic deterrence. It acknowledges wrongdoing and prices it accordingly. Behavioral commitments, by contrast, are forward-looking instruments: they ask a company to promise better conduct going forward. Both have roles in regulatory enforcement. But their application differs critically when the stakes involve public health messaging.

The pharmaceutical industry operates within competitive markets where manufacturers legitimately compete on efficacy, safety profile, manufacturing capacity, and price. These are appropriate battlegrounds. What cannot be appropriate—particularly in vaccines, where public skepticism remains a persistent obstacle to immunization coverage—is comparative marketing that distorts clinical evidence or disparages competitor products through misleading claims.

Sanofi’s alleged conduct, as reported, involved disparaging rival vaccine formulations during a period when vaccine hesitancy was already complicating public health efforts. The specific claims matter less than the categorical principle: when a major vaccine manufacturer deploys marketing tactics designed to undermine confidence in competitor products through methods regulators found sufficiently problematic to open investigation, that behavior demands proportional response.

Here is the core tension. Settlement without sanction may actually incentivize similar conduct by other manufacturers. Consider the cost-benefit calculus from a corporate perspective: if regulatory investigation can be closed through behavioral promises—commitments that are difficult to monitor, enforce across global markets, and verify with precision—while avoiding financial penalty that affects shareholder returns, what deters replication? Behavioral commitments are valuable. They are not sufficient.

I do not argue that every regulatory matter requires maximum penalties. Proportionality and efficiency matter in enforcement. Settlements can expedite justice and preserve regulatory resources. But proportionality must itself be proportional to the harm. Vaccine disparagement campaigns don’t merely harm commercial competitors. They create information asymmetries that affect public decision-making about health. When a citizen reads or hears disparaging claims about a vaccine product, they lack the institutional capacity to verify clinical evidence independently. They rely on the assumption that marketing claims operate within regulatory bounds.

That assumption has now been tested. Sanofi conducted a campaign sufficiently problematic that the EU’s competition authority opened formal investigation. But the company faced no monetary consequences. The EU accepted a promise to cease the conduct and avoid similar behavior prospectively. From a public trust perspective, the message is ambiguous at best: the conduct was wrong enough to investigate, but not wrong enough to penalize.

This ambiguity matters globally. The EU regulatory model influences enforcement approaches elsewhere. When major pharmaceutical markets accept settlement-without-sanction approaches to vaccine marketing misconduct, manufacturers in other jurisdictions—including Georgia—observe precedent. They calibrate their own compliance investments accordingly.

The vaccine sector specifically deserves heightened attention. Unlike many pharmaceutical categories, vaccine uptake depends substantially on public confidence and voluntary participation. Misleading comparative marketing doesn’t merely compete for market share among informed consumers making equivalent choices; it actively shapes the information environment in which public health decisions occur. The negative externality extends beyond commercial competition to population-level immunity and disease control.

I raise this not to demand excessive punishment, but to advocate for proportional accountability. A financial penalty need not be punitive to be meaningful—it must simply reflect the seriousness of the conduct and create incentives for compliance that exceed incentives for violation. Behavioral commitments should augment, not replace, such consequences.

The EU’s investigation itself demonstrates that regulatory mechanisms exist to address this problem. We should ensure those mechanisms carry sufficient force to meaningfully deter repetition. Otherwise, we risk normalizing a tier of acceptable misconduct: misconduct serious enough to investigate but insufficiently serious to penalize—a regulatory gray zone that erodes public trust in the integrity of both industry marketing and regulatory oversight.

Public confidence in vaccines is fragile. We cannot afford regulatory approaches that inadvertently suggest that misleading vaccine marketing carries acceptable costs.